About: Comparative in silico design and validation of GPS™ CoVID‐19 dtec‐RT‐qPCR test

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Comparative in silico design and validation of GPS™ CoVID‐19 dtec‐RT‐qPCR test Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Comparative in silico design and validation of GPS™ CoVID‐19 dtec‐RT‐qPCR test
Creator	Navarro, A Bru, G Erez, L Garc Ia-Sirera, A Mart Inez-Murcia, A Mart Inez-Murcia, Antonio Ros-T Arraga, P
Source	Medline; PMC
abstract	AIMS: Providing a ready‐to‐use reverse transcriptase qPCR (RT‐qPCR) method fully validated to detect the SARS‐CoV‐2 with a higher exclusivity than this shown by early published RT‐qPCR designs. METHODS AND RESULTS: The specificity of the GPS™ CoVID‐19 dtec‐RT‐qPCR test by analysis of sequence alignments was approached and compared with other RT‐qPCR designs. The GPS™ CoVID‐19 dtec‐RT‐qPCR test was validated following criteria of UNE/EN ISO 17025:2005 and ISO/IEC 15189:2012. Diagnostic validation was achieved by two independent reference laboratories, the Instituto de Salud Carlos III, (Madrid, Spain), the Public Health England (Colindale, London, UK), and received the label CE‐IVD. The GPS design showed the highest exclusivity and passed all parameters of validation with strict acceptance criteria. Results from reference laboratories 100% correlated with these obtained by using reference methods and showed 100% of diagnostic sensitivity and specificity. CONCLUSIONS: The CE‐IVD GPS™ CoVID‐19 dtec‐RT‐qPCR test, available worldwide with full analytical and diagnostic validation, is the more exclusive for SARS‐CoV‐2 by far. SIGNIFICANCE AND IMPACT OF THE STUDY: Considering the CoVID‐19 pandemic status, the exclusivity of RT‐qPCR tests is crucial to avoid false positives due to related coronaviruses. This work provides of a highly specific and validated RT‐qPCR method for detection of SARS‐CoV‐2, which represents a case of efficient transfer of technology successfully used since the pandemic was declared.
has issue date	2020-07-29(xsd:dateTime)
bibo:doi	10.1111/jam.14781
bibo:pmid	32652813
has license	no-cc
sha1sum (hex)	8c9a2cf46d918f2422d3234df4fef33755e6b8fd
schema:url	https://doi.org/10.1111/jam.14781
resource representing a document's title	Comparative in silico design and validation of GPS™ CoVID‐19 dtec‐RT‐qPCR test
has PubMed Central identifier	PMC7405274
has PubMed identifier	32652813
schema:publication	J Appl Microbiol
resource representing a document's body	covid:8c9a2cf46d918f2422d3234df4fef33755e6b8fd#body_text
is schema:about of	named entity 'PROVIDES' named entity 'AIMS' covid:arg/8c9a2cf46d918f2422d3234df4fef33755e6b8fd named entity 'qPCR' named entity 'SARS-CoV-2' named entity 'Instituto de Salud Carlos III' named entity 'Colindale' named entity 'reverse transcriptase' named entity 'sensitivity and specificity' named entity 'RT-qPCR' named entity 'RT-qPCR' named entity 'GPS' named entity 'Pangolin' named entity 'SARS' named entity 'SARS-CoV-2' named entity 'GPS' named entity 'GPS' named entity 'severe pneumonia' named entity 'RT-qPCR' named entity 'viruses' named entity 'RdRp' named entity 'Sarbecovirus' named entity 'SARS coronavirus' named entity 'Wuhan' named entity 'Bat' named entity 'Belgium' named entity 'Bat' named entity 'SARS-CoV-2' named entity 'Atlanta' named entity 'SARS-CoV' named entity 'Australia' named entity 'London' named entity 'RdRP' named entity 'RT-qPCR' named entity 'RT-qPCR' named entity 'SARS-CoV-2' named entity 'genome sequencing' named entity 'Bat' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'Pangolin' named entity 'qPCR' named entity 'Atlanta' named entity 'SARS-CoV-2' named entity 'Health Products' named entity 'SARS-CoV-2' named entity 'China' named entity 'SARS' named entity 'real-time PCR' named entity 'genome sequences' named entity 'RT-qPCR' named entity 'ISCIII' named entity 'RT-qPCR' named entity 'false negative' named entity 'SARS' named entity 'public health' named entity 'SARS' named entity 'SARS' named entity 'SARS-CoV-2' named entity 'genomes' named entity 'SARS' named entity 'Spain' named entity 'Bat' named entity 'RdRP' named entity 'SARS-CoV-2' named entity 'China' named entity 'Medical Sciences' named entity 'genomes' named entity 'RT-qPCR' named entity 'first-line' named entity 'SARS-CoV' named entity 'PCR' named entity 'RT-qPCR' named entity 'confidence interval' named entity 'SARS-CoV-2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software